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SIn this study, the 1-year patency of both the sutured and
connector vein grafts was approximately 92%. This com-
pares favorably with other randomized trials in which vein
graft patency was evaluated, but as in most studies involving
novel intraoperative interventions and invasive follow up,
these were highly selected patients. Our patency rates may
have been influenced by our vein sizing criteria; only vein
segments with internal diameters between 3.0 and 4.5 mm
were used, excluding poor quality veins with varicosities
or severe phlebitis. In practice, approximately 10% of
vein segments were believed to be unsuitable; this was not
a common phenomenon. Patients who agree to participate
in a clinical trial may be more health-conscious and more
likely to comply with antiplatelet and cholesterol-lowering
medications, thereby influencing graft patency. Patients
who agree to return for study angiography may be further
self-selecting. However, the characteristics of the 120 pa-
tients returning for graft evaluation did not differ in any mea-
sured variable from the 31 who did not.
The patency rate was 93% in the small number of vein
grafts that were not randomized, suggesting that the good pa-
tency of randomized grafts was not related to selection of op-
timal targets. The patency rate of LITA grafts was 96%,
consistent with expectations for a 1-year assessment. Impor-
tantly, in 10 grafts in which a connector had initially been
implanted, but which had to be replaced with a second con-
nector or converted to a sutured anastomosis owing to tech-
nical issues, patency was 90%. Thus a failed or suboptimal
initial deployment of the device was not associated with re-
duced patency at 1 year. We did note, however, a 3% inci-
dence of stenosis at or near the device in the connector grafts.
One patient had an occipital stroke during follow-up cor-
onary angiography, as the LITA was being instrumented.
This event led to a decision by the data safety and monitor-
ing board to abandon any further conventional angiography
and switch to CT angiography and MRI to assess graft pa-
tency. Although the risk of stroke during angiography is
very low, its potential seriousness raises issues as to whether
conventional angiography continue to be the standard tech-
nique for future graft patency studies. Given the continuing
advances in CT angiography, this modality may become the
de facto standard for investigation.
The history of the St Jude Medical aortic connector sys-
tems illustrates the complexity of the clinical introduction
of new technology and the importance of controlled studies
when evaluating new technical equipment in medicine. Af-
ter promising feasibility studies with short periods of fol-
low-up without controls, the first-generation connector was
widely used and more than 40,000 implants were performed
worldwide. After some time, it became clear that there were
questionable issues with regard to graft patency with the
connector-made anastomosis, and users began to lose confi-
dence in the technology. Reported results with the first-gen-
eration device varied from excellent to poor. In addition toThe Journal of Thoracic and Cathe factors detailed above, it became clear that extreme
care was required during loading of the vein segments
onto the delivery system, and variability in this aspect may
also have contributed to the discrepant results. Ultimately,
owing to the emergence of drug-eluting stents and other fac-
tors, there was a decline in the volumes of CABG and a de-
creasing interest in OPCAB, which may have been the main
market for the device. The decrease in the market for the de-
vice led to St Jude Medical making the decision in Septem-
ber 2004 to discontinue manufacture and sales of the device.
Before that time, developmental work had resulted in the
second-generation device and the multicenter study that
had already been initiated.
In conclusion, this prospective multicenter randomized
controlled trial demonstrated good in-hospital and late clin-
ical outcomes and excellent 1-year patency for vein grafts
anastomosed both by the St Jude Medical second-generation
aortic connector system and by conventional suture tech-
niques. The patency of the connector grafts did not differ
from that of the hand-sutured grafts. Nonrandomized vein
grafts and LITA grafts also had excellent patency rates.
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Dr JohnW.Hammon, Jr (Winston-Salem, NC). This study was
a continued analysis of data that were presented at this meeting last
year. That study also showed that brain injury was magnified byrdiovascular Surgery c Volume 139, Number 3 745




Srewarming whereas the brain was not overtly protected by main-
taining the patient at a hypothermic temperature, thus incriminating
rewarming in the injury profile of two different organ systems. For
the benefit of any perfusionists present and those of us who have
been studying this, I would like to ask you a couple of questions.
You mentioned that rate of rewarming has been shown to be im-
portant. Was rate of rewarming standard in your study or was it de-
termined by the perfusionist or the surgeon, and did you find any
correlation between rate of rewarming and renal injury?
Dr Boodhwani. Thank you very much for those positive com-
ments, Dr Hammon. The rate of rewarming was controlled only
by the fact that patients enrolled in this trial were relatively uniform.
They all underwent straightforward, nonemergency CABG sur-
gery. In those patients we examined the time period over which
the warming occurred, and typically it occurred over a period of
20 to 25 minutes. The temperature change in the rewarmed group
was from 32 C to 37 C. So that was approximately the rate of re-
warming. This was tracked in individual patients but specific corre-
lations for renal function were not performed.
Dr Hammon. The second question relates to the actual temper-
ature of the arterial blood entering the patient’s ascending aorta
through the perfusion cannula. In your manuscript you state that
the temperature was never allowed to rise above 37.5 C. First,
where exactly was that measured? Second, what was the water
bath temperature that the perfusionist set in the pump to achieve
that temperature? In many cases the water bath temperature is as
high as 39 C, which can have differential heating effects on the
blood.
Dr Boodhwani. The study protocol did not control exactly the
water bath temperature. It was controlling the oxygenator outlet
temperatures, though, and oxygenator outlet temperatures were re-
flective of the temperature at which the blood enters the patient’s
body. Those were never allowed to exceed 37.5 C in the normo-
thermic patients and 34.5 C in the patients assigned to mild hypo-
thermia.
Dr Hammon. I have one more question, and it is really more of
a hypothesis than anything else. This morning we heard in an off-
pump study that there is much more elaboration of myocardial en-
zymes in patients undergoing on-pump surgery than off-pump sur-
gery. Could it be elaborated as a hypothesis that one of the reasons
for this would be that the 3 organs in the body that get the most
blood flow during rewarming—the brain, the kidneys, and the
heart—have now been shown to manifest injury? At least 2 of
them have. Could this increased elaboration of enzymes from the
heart also be due to rewarming, and did you collect enzyme data
on your patients that you could study and confirm my humble hy-
pothesis?
Dr Boodhwani. That is actually a very insightful hypothesis.
We did collect cardiac enzyme data in these studies, and we found
that the normothermic patients had higher levels of creatinine ki-
nase. Troponin T levels were only measured in our cohort if the cre-
atinine kinase levels exceeded 800 mg/dL, and troponin levels in
fact were not significantly different in the study. Having said
that, the only additional thing that I would point out is that there
is a key difference between the heart and the other organs: obvi-
ously, the heart undergoes a definite period of ischemia and reper-
fusion, whereas the mechanisms of renal or brain injury that occurs
with cardiopulmonary bypass still remain to be clearly defined,746 The Journal of Thoracic and Cardiovascular Surgwhether it is an ischemic burden or an inflammatory injury.
Many hypotheses have been postulated, and we are still unclear
what the exact effect of temperature is on those mechanisms of in-
jury.
Dr Christina Mora-Mangano (Stanford, Calif). This is an el-
egant paper, and your group has done a number of important stud-
ies on temperature management and end organ dysfunction in
patients undergoing cardiac surgery. However, there are potential
problems regarding your definition of renal dysfunction. The ne-
phrology community has been challenged to agree on a definition
of renal dysfunction. The definition applied in this study differs
from that used by The Society of Thoracic Surgeons database
and is not consistent with definitions that we have used in some
of our work. In your report, 17% of the study patients had postop-
erative renal dysfunction; this is substantially greater than rates re-
ported in the majority of studies assessing perioperative renal
function. Most investigations suggest that 5% to 8% of cardiac sur-
gery patients will have an important compromise in renal function.
Can you address the issues regarding the definition of renal dys-
function? Additionally, in view of the ‘‘inclusive’’ definition of
dysfunction, was there a significant increase in the duration of hos-
pitalization for those patients characterized as having an adverse
renal event?
Dr Boodhwani. Thank you for those very good questions. You
are right. The definition of postoperative renal dysfunction is signif-
icantly debated in the literature. Older studies have used one of two
clinical measures, the first one being postoperative serum creatinine
levels and the second being estimated creatinine clearance using
a variety of different formulas. The incremental increase that con-
stitutes significant renal dysfunction is variable in the literature.
However, a common cutoff that has been used is 25%. A number
of studies have correlated this degree of renal dysfunction with
hard clinical end points of mortality, morbidity, as well as intensive
care unit and hospital stay.
As you mentioned, there was a recent consensus conference by
the Acute Dialysis Quality Initiative to more clearly define renal
dysfunction, and they came up essentially with 3 recommendations.
The first one was that calculated creatinine clearance or urinary pro-
tein measurement should not be used. The second recommendation
was that estimated creatinine clearance should be incorporated into
the definition, if possible. The third recommendation was that
change from baseline is a better indicator of renal dysfunction
than absolute values at any given point in the postoperative period.
We tried to incorporate all these aspects of the definition, and in fact
the risk factor and life expectancy criteria that were described in
that Acute Dialysis Quality Initiative report suggested that a 25%
reduction in estimated creatinine clearance would constitute mild
renal injury.
Having said that, we looked at our cohort and recognized that
this is a relatively low-risk population. Had we chosen a very strin-
gent definition of renal dysfunction, you are right, our renal dys-
function rates would have been much lower, but we probably
would have missed a clinically significant effect of the temperature
intervention. That is why we chose an end point that was fairly fre-
quent in our study population but met the criteria for clinical signif-
icance.
To answer the second part of your question, patients who had re-
nal dysfunction in our study did stay in the hospital an average of 2ery c March 2010
Wiklund et al Evolving Technology/Basic Sciencedays longer than the patients who did not. This has some impact on
clinical outcome.
Dr Mora-Mangano. I would like to make one more comment
about the question regarding the rate of rewarming after hypother-
mic cardiopulmonary bypass. I believe that we still lack the data to
assess the impact of the rate of warming on perioperative adverse
outcomes. Currently available studies should undergo careful scru-
tiny. In most reports, subjects in the rapid-rewarming group achieve
greater absolute temperatures than do those patients rewarmed
more slowly. Thus it is unclear as to whether or not we are assessing
and comparing the actual rewarming rate or the highest temperature
achieved in the study groups.
Dr Bruce B. Davis (Malvern, Australia). I have enjoyed your
work over the years. Your maximum blood temperature of
37.5C seems to be higher than what we would have used, and I
am not sure I picked up your incremental rate of warming. Can
you comment on that first?
Dr Boodhwani. As a pretext to these studies, we conducted
a survey of various Canadian centers looking at temperature prac-
tices and found that in some cases people exceed 37.5C. This sur-The Journal of Thoracic and Cavey was conducted in the 1990s, and perhaps that information is
a bit outdated. But about 30% of centers at that time were exceeding
temperatures of 38C.We believed at the time of the design of these
studies that 37.5C was a safe temperature to be the ceiling temper-
ature that we would permit in these trials.
Dr Davis. And the incremental rate of warming?
Dr Boodhwani. By that you mean the rate over which the tem-
perature changes?
Dr Davis. Yes.
Dr Boodhwani. In this study that occurred over a period of 20 to
25 minutes for a 5C change in temperature.
Dr Davis. Did you have any problems with postoperative and
intensive care, which we would have if we did not rewarm the pa-
tients? Were they intubated for much longer?
Dr Boodhwani. That is a great point. In the second study in
which sustained hypothermia was compared with normothermia,
there was in fact a trend toward sooner discharge from the intensive
care unit in the hypothermic patients. So actually there was no det-
rimental effect of hypothermia in terms of length of ventilation or
length of intensive care unit stay, bleeding, or infection rates.rdiovascular Surgery c Volume 139, Number 3 747
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